Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
1 minute read

Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned

By Vandana Singh
December 27, 1:42 PM
With recent merger and acquisition deals in the targeted radiopharmaceutical therapy (TRT) space, on Tuesday, Oppenheimer noted that Fusion Pharmaceuticals Inc (NASDAQ: FUSN) is potentially the sole remaining clinical-stage player with a robust supply chain. 

AZN

Read More
4 minute read

Why RayzeBio Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session

By Avi Kapoor
December 26, 2:48 PM
Shares of RayzeBio, Inc. (NASDAQ: RYZB) rose sharply during Tuesday’s session after the company announced that it will be acquired by Bristol Myers Squibb for $62.50 per share in cash in a deal worth $4.1 billion. RayzeBio shares gained 100% to $61.38 on Tuesday.

AAOI

Read More
1 minute read

Fusion Pharmaceuticals Poised For Leadership In Targeted Cancer Therapies: Oppenheimer

By Vandana Singh
September 29, 12:21 PM
Oppenheimer initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN), citing the company's pipeline as among the best in the space with alpha-emitter-based targeted radionuclide therapies (TRTs), with three currently in clinical development.

FUSN